Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14584223 | 0.87 | HPGD (0.67) | POLBHPGDHTTRAB9AKMT2A | |
| SCHEMBL9926520 | 0.80 | MEN1 (0.55) | HPGDRAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL9926533 | 0.78 | SMN1; SMN2 (0.66) | HPGDHTTRAB9AKMT2ANPC1 | |
| SCHEMBL9926518 | 0.77 | NPC1 (0.57) | POLBHTTKMT2ANPC1ANO1 | |
| SCHEMBL21019010 | 0.75 | POLB (0.58) | POLBHPGDHTTRAB9AKMT2A | |
| SCHEMBL14297335 | 0.75 | POLB (0.78) | POLBHPGDRAB9AKMT2ANPC1 | |
| SCHEMBL14811383 | 0.75 | MAPT (0.70) | POLBHPGDRAB9AKMT2ANPC1 | |
| SCHEMBL22307422 | 0.74 | POLB (0.68) | POLBHPGDHTTRAB9AKMT2A | |
| SCHEMBL5164362 | 0.74 | POLB (0.60) | POLBHPGDRAB9AKMT2ANPC1 | |
| SCHEMBL28478191 | 0.74 | POLB (1.00) | POLBHPGDRAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | POLB 2312/4885HPGD 2850/4885HTT 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.